194 related articles for article (PubMed ID: 28406838)
1. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2017 May; 42(5):1-6. PubMed ID: 28406838
[TBL] [Abstract][Full Text] [Related]
2. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
[TBL] [Abstract][Full Text] [Related]
3. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
Bassetti M; Labate L; Vena A; Giacobbe DR
Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
[TBL] [Abstract][Full Text] [Related]
4. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
5. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
Li R; Nailor MD
Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
[TBL] [Abstract][Full Text] [Related]
6. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
7. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
[TBL] [Abstract][Full Text] [Related]
8. Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.
Thomas G; Henao-Martínez AF; Franco-Paredes C; Chastain DB
Int J Antimicrob Agents; 2020 Sep; 56(3):106069. PubMed ID: 32603683
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
Ramdeen S; Boucher HW
Expert Opin Pharmacother; 2015; 16(13):2073-81. PubMed ID: 26239321
[TBL] [Abstract][Full Text] [Related]
10. In brief: Oritavancin (Kimyrsa) for skin and skin structure infections.
Med Lett Drugs Ther; 2021 Aug; 63(1631):e1-e2. PubMed ID: 34544104
[No Abstract] [Full Text] [Related]
11. Advantages of Outpatient Treatment with Long-Acting Lipoglycopeptides for Serious Gram-Positive Infections: A Review.
Krsak M; Morrisette T; Miller M; Molina K; Huang M; Damioli L; Pisney L; Wong M; Poeschla E
Pharmacotherapy; 2020 May; 40(5):469-478. PubMed ID: 32239771
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of multi-dose oritavancin and dalbavancin for complicated infections: A propensity score-matched analysis.
Steuber TD; Gipson H; Boyett B; Belk M; Thayer B; Edwards J
Int J Antimicrob Agents; 2024 Jun; 63(6):107165. PubMed ID: 38570019
[TBL] [Abstract][Full Text] [Related]
13. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
[TBL] [Abstract][Full Text] [Related]
14. Review of oritavancin for the treatment of acute bacterial skin and skin structure infections.
García Robles AA; López Briz E; Fraga Fuentes MD; Asensi Diez R; Sierra Sánchez JF
Farm Hosp; 2018 Mar; 42(2):73-81. PubMed ID: 29501059
[TBL] [Abstract][Full Text] [Related]
15. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
[TBL] [Abstract][Full Text] [Related]
16. Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Corey GR; Loutit J; Moeck G; Wikler M; Dudley MN; O'Riordan W;
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358292
[TBL] [Abstract][Full Text] [Related]
17. Beyond Vancomycin: The Tail of the Lipoglycopeptides.
Klinker KP; Borgert SJ
Clin Ther; 2015 Dec; 37(12):2619-36. PubMed ID: 26658277
[TBL] [Abstract][Full Text] [Related]
18. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections.
Morrisette T; Miller MA; Montague BT; Barber GR; McQueen RB; Krsak M
J Antimicrob Chemother; 2019 Aug; 74(8):2405-2416. PubMed ID: 31322694
[TBL] [Abstract][Full Text] [Related]
19. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
20. Antibiotics.
Dalal KS; Bridgeman MB
Nursing; 2017 Mar; 47(3):70. PubMed ID: 28225406
[No Abstract] [Full Text] [Related]
[Next] [New Search]
